APA (7th ed.) Citation

CCB, P., SM, d. B., ME, P., L, M., D, K., P, B., . . . CL, C. (2025). Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial. The Lancet. Oncology, 26(10), 1370. https://doi.org/10.1016/S1470-2045(25)00379-1

Chicago Style (17th ed.) Citation

CCB, Post, et al. "Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women with High-risk Endometrial Cancer (PORTEC-3): 10-year Clinical Outcomes and Post-hoc Analysis by Molecular Classification from a Randomised Phase 3 Trial." The Lancet. Oncology 26, no. 10 (2025): 1370. https://doi.org/10.1016/S1470-2045(25)00379-1.

MLA (9th ed.) Citation

CCB, Post, et al. "Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women with High-risk Endometrial Cancer (PORTEC-3): 10-year Clinical Outcomes and Post-hoc Analysis by Molecular Classification from a Randomised Phase 3 Trial." The Lancet. Oncology, vol. 26, no. 10, 2025, p. 1370, https://doi.org/10.1016/S1470-2045(25)00379-1.